News Quantified

TENX – tenax therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Tenax Therapeutics: A Binary Bet With Heavy Downside Likely [Seeking Alpha]

Tenax Therapeutics (TENX) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $35.00 price target on the stock.

Tenax Therapeutics (TENX) had its price target raised by Guggenheim from $25.00 to $34.00. They now have a "buy" rating on the stock.

Tenax Therapeutics (TENX) was upgraded by Lifesci Capital to "strong-buy".

Tenax Therapeutics (TENX) had its "outperform" rating reaffirmed by William Blair.

Cantor Fitzgerald

Cantor Fitzgerald

CANTOR FITZGERALD

Form EFFECT TENAX THERAPEUTICS, INC.

Form S-3 TENAX THERAPEUTICS, INC.

Form SCHEDULE 13D TENAX THERAPEUTICS, INC. Filed by: Giordano Christopher Thomas

Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31

Form 8-K TENAX THERAPEUTICS, INC. For: Mar 10

Top News Gainers

10/31 Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial 7.4%

1/15 Tenax Therapeutics Inc (NASDAQ: TENX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%

6/14 Form 8-K TENAX THERAPEUTICS, INC. For: Jun 13 4.7%

1/22 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.3%

8/23 Tenax Therapeutics Provides Clinical Development Update 3.4%

8/30 Form S-8 TENAX THERAPEUTICS, INC. 2.5%

11/8 Form 8-K/A TENAX THERAPEUTICS, INC. For: Jun 13 2.5%

4/29 Form 8-K TENAX THERAPEUTICS, INC. For: Apr 24 2.3%

3/30 Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 2.1%

2/14 Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: Iroquois Capital Management, LLC 0.0%

Top News Decliners

3/13 Form 8-K TENAX THERAPEUTICS, INC. For: Mar 11 -35.8%

2/29 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.8%

1/13 Form 8-K TENAX THERAPEUTICS, INC. For: Jan 13 -7.9%

4/9 Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction -6.7%

2/21 Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board -5.8%

2/7 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: BlackRock Inc. -5.7%

3/27 Form D TENAX THERAPEUTICS, INC. -5.6%

5/15 Q1/2019 3/31/2019 EPS -0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.2%

8/14 Q2/2019 6/30/2019 EPS -0.280 ZacksConsensus -0.450 ActVsEst 0.170 - Beat -4.2%

3/23 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: ARMISTICE CAPITAL, LLC -2.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day